AI-based optimization of the production of cardiac bodies
The biotech start-up myotwin GmbH and the data management company IndiScale GmbH are launching a joint project to optimise the production of artificially manufactured human mini-organs using artificial intelligence.
Timeframe: May 2025 – April 2026
Funding: The project is funded by NBank as part of Lower Saxony’s innovation promotion programme for research and development in companies (co-financed by the European Union).
Artificial organs for heart research
The artificial production of heart muscle tissue offers a promising approach to developing new drugs for cardiovascular diseases, which are the leading cause of death worldwide. The project ‘AI-based optimisation of cardiac body production’ aims to make the production process of cardiac bodies – a precursor to complete heart tissue – more efficient and robust. This should enable the production of high-quality, functional heart tissue, which is essential for research and the development of innovative therapies.
AI and biotechnology
Artificial intelligence will be used in two very specific areas of the project. On the one hand, the complex biotechnological production process itself will be optimised using machine learning. In addition, research with Cardiac Bodies generates a large amount of data. This data is managed by the LinkAhead data management system. To simplify data analysis, LinkAhead’s search language will be greatly simplified through the use of large language models. This will improve complex search queries in particular.
Website of collaboration partner myotwin: https://myotwin.co